Janus Henderson reports 9.77M shares (4.9%) in RVMD

Janus Henderson Group plc filed Amendment No. 4 to a Schedule 13G/A reporting beneficial ownership of 9,766,496 shares of Revolution Medicines, Inc. common stock, representing 4.9% of the class as of 03/31/2026.

Rhea-AI Filing Summary

Janus Henderson Group plc filed Amendment No. 4 to a Schedule 13G/A reporting beneficial ownership of 9,766,496 shares of Revolution Medicines, Inc. common stock, representing 4.9% of the class as of 03/31/2026. The filing states the Asset Managers exercise shared voting and shared dispositive power over the reported shares and disclaims rights to dividends or sale proceeds. The filing notes that none of the Managed Portfolios individually owns more than 5% of the class. The amendment is signed on 5/15/2026.

Insights

Institutional Ownership Analyst

Large passive stake reported by Janus Henderson across managed accounts.

The filing attributes 9,766,496 shares (4.9%) to Janus Henderson Group plc as the parent of multiple registered investment advisers that exercise voting and dispositive discretion for client accounts. The position is reported as shared voting and shared dispositive power, consistent with agency-managed portfolios.

Impact depends on individual managers' client mandates and trading decisions; this schedule is informational and does not itself indicate a change in control or imminent transactions.

Corporate Governance Specialist

The filing clarifies attribution and disclaimers for client-held securities.

The disclosure explains that multiple Asset Managers under Janus Henderson exercise discretion for Managed Portfolios and that dividends/proceeds rights are disclaimed by the Asset Managers. This language signals agency ownership rather than direct corporate control.

Watch subsequent filings from identified advisers for any shifts in voting power or changes that cross the 5% threshold, which would alter regulatory obligations.

Key Figures

Reported shares: 9,766,496 shares Percent of class: 4.9% Shared voting power: 9,766,496 shares +4 more

7 metrics

Reported shares 9,766,496 shares Beneficial ownership as of 03/31/2026

Percent of class 4.9% Percent of Revolution Medicines common stock

Shared voting power 9,766,496 shares Shared power to vote or direct the vote

Shared dispositive power 9,766,496 shares Shared power to dispose or direct disposition

CUSIP 76155X100 Revolution Medicines common stock

Ownership report date 03/31/2026 As-of date for reported ownership

Filing signature date 5/15/2026 Date amendment signed by Head of North America Compliance

Key Terms

Schedule 13G/A, beneficial ownership, shared dispositive power, Managed Portfolios, +1 more

5 terms

Schedule 13G/A regulatory

"Amendment No. 4 to Schedule 13G/A reporting beneficial ownership"

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

beneficial ownership regulatory

"may be deemed to be the beneficial owner of 9,766,496 common stock"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

shared dispositive power regulatory

"Shared power to dispose or to direct the disposition of: 9766496"

Managed Portfolios financial

"collectively referred to herein as Managed Portfolios"

CUSIP technical

"Common Stock 76155X100"

A CUSIP is a nine-character alphanumeric code that uniquely identifies a U.S. or Canadian financial security—such as a stock, bond, or fund share—like a Social Security number for an investment. It matters to investors because brokers, exchanges and record-keepers use the CUSIP to match trades, track ownership, settle transactions and pull accurate records, reducing errors and ensuring money and securities go to the right place.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does Janus Henderson (RVMD) report?

Janus Henderson reports beneficial ownership of 9,766,496 shares, equal to 4.9% of Revolution Medicines common stock as of 03/31/2026. The amount is held across multiple managed portfolios under Janus Henderson.

Does Janus Henderson have sole voting or disposition power in RVMD?

No. The filing states 0 shares with sole voting or sole dispositive power and 9,766,496 shares with shared voting and shared dispositive power, indicating collective manager discretion for those accounts.

Will Janus Henderson receive dividends or proceeds from these RVMD shares?

The Asset Managers disclaim the right to receive dividends or sale proceeds; the Managed Portfolios themselves hold the economic rights, not the Asset Managers in their capacity as managers.

Do any Managed Portfolios own more than 5% of RVMD?

The filing states that none of the Managed Portfolios individually owns more than 5% of Revolution Medicines common stock; the reported 4.9% is an aggregated attribution to Janus Henderson.

What are the relevant dates in the filing?

The ownership is reported as of 03/31/2026 and the amendment is signed on 5/15/2026. These dates anchor the reported share count and the filing signature.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/15/2026 - 11:23 AM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 4)

REVOLUTION MEDICINES, INC.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

76155X100

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 76155X100

1

Names of Reporting Persons

JANUS HENDERSON GROUP PLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

JERSEY

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 9,766,496.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 9,766,496.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

9,766,496.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.9 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

Item 1.
(a)	Name of issuer: REVOLUTION MEDICINES, INC.
(b)	Address of issuer's principal executive offices: 700 SAGINAW DR REDWOOD CITY, CA 94063
Item 2.
(a)	Name of person filing: Janus Henderson Group plc
(b)	Address or principal business office or, if none, residence: 201 Bishopsgate EC2M 3AE, United Kingdom
(c)	Citizenship: Y9
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 76155X100
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: Janus Henderson Group plc (JHG) is the ultimate parent of a number of SEC-registered investment advisers and foreign equivalents thereof, including but not limited to Janus Henderson Investors US LLC, Janus Henderson Investors UK Limited, Janus Henderson Investors Australia Institutional Funds Management Limited, Janus Henderson Investors Middle East Limited, Janus Henderson Investors (Jersey) Limited, Janus Henderson Investors (Japan) Limited, Janus Henderson Investors (Singapore) Limited, Kapstream Capital Pty Limited, Privacore Capital Advisors LLC, Tabula Investment Management Limited, and Victory Park Capital Advisors LLC (each, an Asset Manager and together, the Asset Managers). The Asset Managers generally exercise investment and/or voting discretion on behalf of their clients which include investment companies, other investment advisers, institutional separate accounts and retail separate accounts (collectively referred to herein as Managed Portfolios). As a result of their exercise of investment and/or voting discretion on behalf of the Managed Portfolios, the Asset Managers may be deemed to be the beneficial owner of 9,766,496 common stock of Revolution Medicines, Inc. However, the Asset Managers do not have the right to receive any dividends from, or the proceeds from the sale of, the securities held in the Managed Portfolios and disclaim any ownership associated with such rights.
(b)	Percent of class: 4.9 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 9766496
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 9766496
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. The Managed Portfolios have the right to receive all dividends from, and the proceeds from the sale of, the securities held in their respective accounts. Of the Managed Portfolios, none own more than five percent of the common stock of Revolution Medicines, Inc.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. Please refer to Exhibit 99.
Item 8.	Identification and Classification of Members of the Group.
	If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group. N/A
Item 9.	Notice of Dissolution of Group.
	Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5. N/A

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

JANUS HENDERSON GROUP PLC

Signature:	Kristin Mariani
Name/Title:	Head of North America Compliance
Date:	5/15/2026

Exhibit Information

Exhibit 24: Power of Attorney Exhibit 99: Item 7